Literature DB >> 7364911

Electron-capture gas chromatography of plasma sulphonylureas after extractive methylation.

P Hartvig, C Fagerlund, O Gyllenhaal.   

Abstract

Conditions for the extractive alkylation of eight sulphonylurea hypoglycemic drugs have been evaluated. Extractive methylation of the compounds was achieved within 90 min using tetrabutylammonium as counter-ion (0.1 M at pH = 6.9) with 5% methyl iodide in dichloro-methane as organic phase. Mass spectral analysis showed derivatives methylated at the sulphonamide nitrogen. A higher pH or use of tetrapentylammonium as counter-ion caused hydrolysis of the sulphonylureas. The derivatives showed a high electron-capture response with minimum concentrations detectable in the range 1-4 x 10(-16) moles sec-1. Therapeutic plasma concentrations of glipzide and tolbutamide were determined by direct extractive methylation of the compounds from the plasma sample. The glipizide derivative was determined by electron-capture gas chromatography down to about 20 ng/ml in a 0.5-ml plasma sample. The relative standard deviation at the 0.2 microgram/ml level of glipizide was 6% (n = 6). The corresponding figure in the determination of tolbutamide at the 10 microgram/ml level was 3% (n = 10).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7364911     DOI: 10.1016/s0378-4347(00)81264-5

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Development and validation of RP-HPLC-UV method for the determination of Glipizide in human plasma.

Authors:  M Atif; S H Khalid; G L Onn Kit; S A S Sulaiman; M Asif; A Chandersekaran
Journal:  J Young Pharm       Date:  2013-03-09

Review 2.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

3.  Rapid Analysis of Glibenclamide Using an Environmentally Benign Stability-Indicating RP-HPLC Method.

Authors:  Nazrul Haq; Fars Kaed Alanazi; Ibrahim Abdullah Alsarra; Faiyaz Shakeel
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.